AbbVie’s aesthetics business shrank slightly in the third quarter of 2026, but the total hides two very different trends. Sales of Botox Cosmetic rose, while sales of the Juvéderm range of hyaluronic acid fillers fell by almost 12%.
The company reported global aesthetics net revenues of $1,176 million for July to September 2026, down 1.4% on the same quarter last year (down 1.8% on an operational basis, which strips out currency effects). The figures were published on 30 October in AbbVie’s quarterly results.
What the numbers show
Botox Cosmetic generated $669 million worldwide, up 4.9%. Growth was stronger outside the United States: international sales rose 8.6% to $281 million, while US sales rose 2.4% to $388 million.
Juvéderm moved the other way. Global sales fell 11.9% to $222 million. The decline was steepest internationally, down 15.4% to $132 million, with US sales down 6.3% to $90 million.
AbbVie’s “other aesthetics” line, which includes body contouring and skincare brands, fell 6.0% to $285 million.
Over the first nine months of 2026, Botox Cosmetic sales reached $2,065 million (+9.5%), while Juvéderm reached $699 million (−6.0%). Total aesthetics revenue for the nine months was $3,644 million, up 2.0%.
The pipeline
The results release repeated that the US Food and Drug Administration has accepted AbbVie’s application to add masseter muscle prominence to Botox Cosmetic’s label. If approved, it would be the first US neurotoxin indication for this use. AbbVie gave no new timeline.
According to summaries of the earnings call, executives also said AbbVie plans to resubmit its US application for trenibotulinumtoxinE, a fast-onset, short-acting type E toxin, before the end of 2026. The FDA issued a complete response letter for that product in April 2026, and the company has described the issues as manufacturing-related rather than safety or efficacy. Executives were also reported to have said a phase 2 study combining Botox with trenibotulinumtoxinE in frown lines has begun. Editor check: confirm these call remarks against the official webcast before publication.
Abbvie Q3 aesthetics results: Why it matters
AbbVie is the largest company in medical aesthetics, so its numbers act as a barometer for the wider market. This quarter suggests demand for toxin treatments is holding up, while demand for fillers remains weak.
Several explanations are discussed in the industry, though AbbVie’s release does not break them down. Fillers are more expensive per visit and more sensitive to consumer spending. Competition from lower-priced fillers and from biostimulators has grown. Rapid weight loss with GLP-1 medicines has also changed how some patients and clinicians think about facial volume. None of these can be tested from one company’s sales figures.
For clinics, a continued shift toward toxins and away from volumising fillers may affect treatment mix and pricing. For patients, it is a reminder that market trends do not change the clinical evidence for any individual treatment.
Limitations
These are company-reported revenues, not independent data. They do not separate price from volume, and they cover a single quarter. International figures are affected by currency movements and by changes in distribution. Statements from the earnings call quoted here come from secondary transcript summaries.
Key takeaways
AbbVie’s Q3 2026 aesthetics revenue fell 1.4% to $1,176 million.
Botox Cosmetic grew 4.9%, while Juvéderm fell 11.9%, with the sharpest drop outside the US.
AbbVie reportedly plans to resubmit trenibotulinumtoxinE in the US before year-end; the masseter application is still under FDA review.
Original sources
AbbVie Reports Third-Quarter 2026 Financial Results, AbbVie, 30 Oct 2026
This article is published by Aesthetics.news for general information and educational purposes only. It does not constitute medical advice, diagnosis or treatment, and should not replace a consultation with a qualified healthcare professional. Treatments and outcomes may vary from person to person. Readers should seek advice from an appropriately qualified professional before making decisions about their health or treatment. In a medical emergency, seek immediate medical assistance.